ChromaDex Corporation (CDXC): Price and Financial Metrics

ChromaDex Corporation (CDXC): $1.92

-0.19 (-9.00%)

POWR Rating

Component Grades













Add CDXC to Watchlist
Sign Up

Industry: Chemicals



in industry


  • CDXC scores best on the Quality dimension, with a Quality rank ahead of 65.87% of US stocks.
  • CDXC's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • CDXC ranks lowest in Momentum; there it ranks in the 14th percentile.

CDXC Stock Summary

  • The ratio of debt to operating expenses for ChromaDex Corp is higher than it is for about merely 11.74% of US stocks.
  • With a year-over-year growth in debt of 187.23%, ChromaDex Corp's debt growth rate surpasses 94.05% of about US stocks.
  • The volatility of ChromaDex Corp's share price is greater than that of 95.13% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to ChromaDex Corp, a group of peers worth examining would be SREV, CXDO, HAYN, VMD, and BXRX.
  • Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to

CDXC Valuation Summary

  • In comparison to the median Healthcare stock, CDXC's price/sales ratio is 17.18% lower, now standing at 9.4.
  • Over the past 150 months, CDXC's EV/EBIT ratio has gone down 20.7.
  • Over the past 150 months, CDXC's price/earnings ratio has gone down 21.9.

Below are key valuation metrics over time for CDXC.

Stock Date P/S P/B P/E EV/EBIT
CDXC 2021-08-31 9.4 13.8 -25.0 -23.6
CDXC 2021-08-30 9.1 13.4 -24.3 -22.8
CDXC 2021-08-27 9.3 13.6 -24.7 -23.2
CDXC 2021-08-26 9.0 13.3 -24.0 -22.6
CDXC 2021-08-25 8.9 13.1 -23.7 -22.3
CDXC 2021-08-24 8.9 13.1 -23.8 -22.3

CDXC Growth Metrics

    The 2 year price growth rate now stands at 29.19%.
  • Its 3 year net income to common stockholders growth rate is now at -2128.97%.
  • Its 3 year net cashflow from operations growth rate is now at -352.14%.
CDXC's revenue has moved up $32,411,000 over the prior 34 months.

The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 67.449 -24.163 -27.128
2021-09-30 65.135 -19.197 -27.9
2021-06-30 62.007 -17.123 -23.259
2021-03-31 59.595 -10.784 -21.404
2020-12-31 59.257 -10.6 -19.925
2020-09-30 56.901 -11.232 -22.681

CDXC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
  • CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
  • MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.

The table below shows CDXC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.115 0.615 -3.082
2021-06-30 1.178 0.612 -2.751
2021-03-31 1.276 0.607 -3.100
2020-12-31 1.545 0.595 -2.616
2020-09-30 1.466 0.586 -2.883
2020-06-30 1.361 0.577 -2.841

CDXC Price Target

For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.80 Average Broker Recommendation 1.3 (Strong Buy)

CDXC Stock Price Chart Interactive Chart >

Price chart for CDXC

CDXC Price/Volume Stats

Current price $1.92 52-week high $10.78
Prev. close $2.11 52-week low $1.51
Day low $1.85 Volume 6,541,000
Day high $2.24 Avg. volume 533,672
50-day MA $1.89 Dividend yield N/A
200-day MA $3.68 Market Cap 131.20M

ChromaDex Corporation (CDXC) Company Bio

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.

CDXC Latest News Stream

Event/Time News Detail
Loading, please wait...

CDXC Latest Social Stream

Loading social stream, please wait...

View Full CDXC Social Stream

Latest CDXC News From Around the Web

Below are the latest news stories about ChromaDex Corp that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022

LOS ANGELES, February 22, 2022--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Yahoo | February 22, 2022

ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside

LOS ANGELES, February 09, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. ChromaDex currently holds a robust patent portfolio of over 40 granted or licensed patents relating to Niagen® (patented NR) and other precursors to NAD, a molecule at the forefront of the healthy aging and cellular health categories. Niage

Yahoo | February 9, 2022

ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

LOS ANGELES, January 31, 2022--ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program’s (CERP™) 100th published peer-reviewed study on the company’s flagship ingredient Niagen® (patented nicotinamide riboside, or "NR") and other proprietary ingredients. CERP, the program pioneering NR research, is the first-of-its-kind to reach such a milestone. The recently published preclinical trial in the Investigative Ophthalmology & Visual Science Journal investigated the effects

Yahoo | January 31, 2022

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

LOS ANGELES, January 25, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or "NR") ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of ChromaDex’s proprietary NR ingredient in monocytes (a type of white blood cell) extracted from two groups: young, healthy subjects and patients diagnosed with system

Yahoo | January 25, 2022

We Think ChromaDex (NASDAQ:CDXC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | January 22, 2022

Read More 'CDXC' Stories Here

CDXC Price Returns

1-mo 6.67%
3-mo -19.67%
6-mo -50.13%
1-year -79.04%
3-year -58.53%
5-year -49.74%
YTD -48.66%
2021 -22.08%
2020 11.37%
2019 25.66%
2018 -41.67%
2017 77.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5303 seconds.